Several other research analysts have also recently issued reports on the stock. Peel Hunt restated a buy rating on shares of Motif Bio in a report on Thursday, May 31st. Northland Capital Partners restated a buy rating on shares of Motif Bio in a report on Monday, June 11th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. The company presently has an average rating of Buy and an average price target of GBX 109.40 ($1.40).
Shares of Motif Bio stock opened at GBX 33.36 ($0.43) on Tuesday. Motif Bio has a 52-week low of GBX 23.50 ($0.30) and a 52-week high of GBX 51.75 ($0.66).
Motif Bio plc, a clinical stage biopharmaceutical company, develops and commercializes pharmaceutical formulations in the United States. The company develops novel antibiotics for the treatment of serious and life-threatening infections caused by multi-drug resistant bacteria. Its lead product candidate is iclaprim, a novel antibiotic that is in Phase III clinical trials to treat bacterial infections, such as acute bacterial skin and skin structure infections, and hospital-acquired bacterial pneumonia caused by methicillin-resistant staphylococcus aureus, as well as to treat lung infections caused by Staphylococcus aureus in patients with cystic fibrosis.
Further Reading: Trading Strategy Examples and Plans
Receive News & Ratings for Motif Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Motif Bio and related companies with MarketBeat.com's FREE daily email newsletter.